Seeking Alpha

Spectrum Pharmaceuticals (SPPI) +4.3%, with the main news being that the biotech has started a...

Spectrum Pharmaceuticals (SPPI) +4.3%, with the main news being that the biotech has started a Phase 1 trial evaluating the safety and tolerability of its RenaZorb drug in healthy volunteers. RenaZorb is a potential treatment of hyperphosphatemia (high phosphate levels in the blood) in patients with chronic kidney disease. (PR)
Comments (1)
  • Jonha's Pop
    , contributor
    Comments (67) | Send Message
     
    If someone out there has the April numbers of prescription orders, for Fusilev (A SPPI product) usually published monthly by Wolter skluwer, it would be most appreciated, if you would publish them.
    31 May 2012, 04:43 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs